CTRI/2015/07/006001CompletedPhase 4
Evaluate the efficacy of Curcumin & Piperine as an antioxidant adjuvant to intralesional dexamethasone injections in the management of Oral Submucous Fibrosis
Dr Nilima Sharma0 sites41 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- Phase 4
- Status
- Completed
- Sponsor
- Enrollment
- 41
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Patients of either sex above 20 years of age.
- •A positive history of chewing arecanut or one of its commercial preparations.
- •Diagnosis of OSMF was made on the basis of natural history and characteristic clinical features which included the presence of burning sensation in the mouth, intolerance to spicy food, blanching and loss of suppleness of oral mucosa, presence of palpable fibrous bands and decreased mouth opening.
Exclusion Criteria
- •Patients with chronic illnesses and systemic diseases(diabetes, hypertension, liver disorders, kidney disorders, autoimmune disorders), other mucosal lesions.
- •Pregnant and lactating women.
- •Patients with a known allergy or contraindication to the study drugs.
- •Temporomandibular joint arthrosis , Fracture mandible ramus
Investigators
Similar Trials
Not yet recruiting
Phase 3
Evaluation of the effects of curcumin-piperine in reducing Pseudomonas infection and improving clinical outcome in patients with cystic fibrosisCystic fibrosiscystic fibrosis.IRCT20221229056976N1Mashhad University of Medical Sciences138
Completed
Phase 3
The effects of curcumin-piperne supplementation on CABG patientIRCT20201129049534N480
Recruiting
Phase 3
The effect of curcumin on rheumatoid arthritisIRCT20120701010149N3Esfahan University of Medical Sciences60
Recruiting
Not Applicable
curcumin-piperine supplementation in children with none- alcoholic fatty liver diseaseIRCT20171107037302N2Esfahan University of Medical Sciences60
Recruiting
Phase 3
Curcumin-piperine supplementation in children with none- alcoholic fatty liver diseaseIRCT20121216011763N54Esfahan University of Medical Sciences60